Literature DB >> 3756928

Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads.

C P Reynolds, R C Seeger, D D Vo, A T Black, J Wells, J Ugelstad.   

Abstract

Variables effecting removal of neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads were studied. Human neuroblastoma cell lines were labeled with the supravital DNA stain Hoechst 33342, seeded into normal bone marrow, incubated with monoclonal antibodies recognizing neuroblastoma cell surface antigens (HSAN 1.2, antibody 459, antibody 390, BA-1, and Leu-7), and then mixed with magnetic microspheres coated with goat anti-mouse immunoglobulin. Tumor cells that attached to the magnetic immunobeads were then removed from the marrow with magnets. The efficacy of tumor cell removal depended on the amount of monoclonal antibody bound to tumor cells and the immunobead/tumor cell ratio. In addition, two cycles of purging with both monoclonal antibodies and immunobeads was superior to one cycle. Using a cocktail of the five antibodies, 3 to 4 logs of tumor cells could be depleted from marrow with good recovery of viable hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756928

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Stem cell transplantation for neuroblastoma.

Authors:  J D Fish; S A Grupp
Journal:  Bone Marrow Transplant       Date:  2007-11-26       Impact factor: 5.483

2.  Peripheral dose heterogeneity due to the thread effect in total marrow irradiation with helical tomotherapy.

Authors:  Yutaka Takahashi; Michael R Verneris; Kathryn E Dusenbery; Christopher T Wilke; Guy Storme; Daniel J Weisdorf; Susanta K Hui
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-09-05       Impact factor: 7.038

3.  Multi-institutional feasibility study of a fast patient localization method in total marrow irradiation with helical tomotherapy: a global health initiative by the international consortium of total marrow irradiation.

Authors:  Yutaka Takahashi; Stefano Vagge; Stefano Agostinelli; Eunyoung Han; Lukasz Matulewicz; Kai Schubert; Ravishankar Chityala; Vaneerat Ratanatharathorn; Koen Tournel; Jose A Penagaricano; Sterzing Florian; Marc-Andre Mahe; Michael R Verneris; Daniel J Weisdorf; Renzo Corvo; Kathryn E Dusenbery; Guy Storme; Susanta K Hui
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-30       Impact factor: 7.038

4.  Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.

Authors:  D S Hoon; C T Kuo; S Wen; H Wang; L Metelitsa; C P Reynolds; R C Seeger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 5.  Immunology and immunotherapy of neuroblastoma.

Authors:  Robert C Seeger
Journal:  Semin Cancer Biol       Date:  2011-09-28       Impact factor: 15.707

Review 6.  Neuroblastoma: issues in transplantation.

Authors:  Stephan A Grupp; Shahab Asgharzadeh; Gregory A Yanik
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

Review 7.  Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors.

Authors:  David Barrett; Jonathan D Fish; Stephan A Grupp
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

8.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Authors:  Susan G Kreissman; Robert C Seeger; Katherine K Matthay; Wendy B London; Richard Sposto; Stephan A Grupp; Daphne A Haas-Kogan; Michael P Laquaglia; Alice L Yu; Lisa Diller; Allen Buxton; Julie R Park; Susan L Cohn; John M Maris; C Patrick Reynolds; Judith G Villablanca
Journal:  Lancet Oncol       Date:  2013-07-25       Impact factor: 41.316

Review 9.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.